Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty

Launched by RHODE ISLAND HOSPITAL · Mar 30, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at how two different pain management methods work after total knee replacement surgery. The researchers want to see if using systemic lidocaine (a medication given through an IV) is as effective as an ultrasound-guided adductor canal block (an injection that numbs a specific area of the thigh) in helping patients manage their pain after surgery.

To participate, patients should be between the ages of 65 and 74 and classified as ASA PS 1 to 3, which means they are generally healthy or have mild to moderate health issues. However, individuals with more serious health problems, certain nerve conditions, or those taking opioids for a long time are not eligible. If you decide to take part in this study, you will receive either the lidocaine treatment or the block and be monitored for how well it helps with your pain after the surgery. This trial will help doctors understand the best ways to manage pain for patients like you after knee replacement surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ASA PS 1-3 patients undergoing primary, unilateral total knee arthroplasty
• Exclusion Criteria:
• • ASA PS classification of 4 or greater
• • Pre-existing neuropathy
• • Coagulopathy
• • Chronic opioid consumption (\>3 months)
• • Infection at the site
• • Known allergy to study medications (lidocaine)
• • High grade atrioventricular block (cardiac conduction system impairment)
• • A history of CVA/TIA
• • Currently using lidocaine patches
• • Known liver disease